Krystal Biotech Has Completed The Sale Of Its Rare Pediatric Disease Priority Review Voucher For $100M
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $100M. The company was awarded the voucher following FDA accelerated approval of VYJUVEK for recessive or dominant dystrophic epidermolysis bullosa (DEB) for patients 6 months of age and older.
August 21, 2023 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech's sale of its Rare Pediatric Disease Priority Review Voucher could provide a significant financial boost to the company.
The sale of the voucher for $100M could significantly improve Krystal Biotech's financial position. This could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100